A billion-dollar biopic becomes a franchise
The Michael Jackson biopic sequel is the planned second installment in Lionsgate’s dramatized film series about the pop icon’s life and career, following a first movie that ended mid‑“Bad” tour and turned a heavily controlled, controversy‑dodging portrait of Jackson into a record‑breaking box office phenomenon that now demands a more ambitious, more honest follow‑up. That is the real story behind the new Michael Jackson biopic sequel: a studio sitting on a $1 billion biopic box office success and choosing franchise over finality. If the first film treated Jackson as myth, the second is the moment the myth runs head‑first into unresolved history. The sequel is less a surprise than an inevitability, but whether it earns its existence will depend on how far it’s willing to move beyond fan‑service and estate‑approved nostalgia.
Timeline: Lionsgate wants Michael back on screens by 2027–2028
The sequel’s schedule tells you how aggressively Lionsgate is treating Michael Jackson as franchise material. Lionsgate’s chairman Adam Fogelson says the studio is targeting a production start toward the end of this year or early next year, with a release roughly in late 2027 or the first half of 2028. In other words, a new Michael Jackson film in 2027 is not a distant dream but an active production goal. That pace is more in line with superhero follow‑ups than painstaking music biographies, and it signals confidence that audiences will return for another two‑plus hours of reconstructed concerts and dramatized backstage drama. It also suggests the sequel will lean on material already shot, with Fogelson confirming that several unused “big musical sequences” from the first movie are almost certain to be repurposed. This is efficient franchise thinking, but it raises a question: is the priority depth or speed?
From record-breaking hit to $1 billion franchise machine
No matter what critics thought, Michael proved that the appetite for pop‑star mythology is huge. The film, directed by Antoine Fuqua and starring Jackson’s nephew Jaafar Jackson, took in more than a billion dollars worldwide, making it the highest‑grossing biopic of all time and dethroning an earlier music‑industry hit at the top of the biopic box office rankings. That kind of success rewrites risk calculations. According to comments made by Fogelson, the team is focused on delivering “the biggest, best sequel” at the right price for audiences who embraced the first film. With that mandate, Michael 2 is positioned less as a standalone story than as the next chapter in a lucrative Lionsgate Michael Jackson series. Franchising Jackson’s life is a bold commercial move: his catalogue, persona, and iconography can support multiple films, but treating a complicated human story as an expandable IP universe is a creative gamble.
What the sequel could cover—and what it can’t keep dodging
The first film ends mid‑1987 “Bad” tour, leaving vast territory for a sequel: the later tours, artistic reinventions, creative struggles, health issues, and the intense media circus around Jackson’s private life. Fogelson has already said there is a “massive amount of music… and life experiences separate and apart from allegations… that would fill more than a second movie on its own.” That phrasing is telling. The first film was heavily criticized as a sanitized hagiography, with contentious elements from his early life removed and a reported estate‑funded reshoot erasing mentions of sexual abuse allegations in the final act. Now the sequel faces a choice. It can double down on the translucent, controversy‑free approach that pleased some fans, or it can accept that Jackson’s story is incomplete without grappling with the allegations and legal entanglements that defined much of his later years. The audience has already rewarded nostalgia; the next chapter will test how much truth they are willing to confront.
Can Lionsgate balance fandom, legacy, and scrutiny?
Fogelson insists the team is “fully engaged with everybody” to make a sequel worthy of the enthusiasm surrounding Michael, and the studio is clearly intent on protecting a valuable asset. But a Michael Jackson biopic sequel cannot stay insulated forever. The first film’s estate‑shaped narrative showed how legal clauses and financial muscle can reshape a supposedly definitive life story, even forcing the removal of an entire thread about abuse allegations in late‑stage reshoots. If the second film repeats that pattern, the franchise risks hardening into glossy myth rather than meaningful biography. The most interesting path forward is also the hardest: a follow‑up that keeps the spectacle and music that audiences love while admitting that Jackson’s legacy is contested, painful, and unresolved. The production timeline is set, the Michael Jackson film planned for 2027–2028 is on the way, and the box office foundation is secure. The only real suspense now is whether Lionsgate is ready to tell a story as complex as its subject.
